A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities

समान संसाधन

• Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h
  द्वारा: Cheng, Karen, और अन्य
  प्रकाशित: (2019)
• Baseline Characteristics and Outcomes Among Patients with Complicated Skin and Soft Tissue Infections Admitted to the Intensive Care Unit: Analysis of the Phase 3 COVERS Randomized Trial of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam
  द्वारा: Sánchez-García, Miguel, और अन्य
  प्रकाशित: (2020)
• Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections
  द्वारा: Das, Shampa, और अन्य
  प्रकाशित: (2019)
• CANVAS 1 and 2: Analysis of Clinical Response at Day 3 in Two Phase 3 Trials of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in Treatment of Acute Bacterial Skin and Skin Structure Infections
  द्वारा: Friedland, H. David, और अन्य
  प्रकाशित: (2012)
• Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil
  द्वारा: Matzneller, Peter, और अन्य
  प्रकाशित: (2016)